TetraLogic Pharmaceuticals' Smac Mimetic Birinapant Selected for Oral Presentation at the 17th Japanese Foundation for Cancer ResearchInternational Symposium on Cancer Chemotherapy  
12/6/2012 11:11:12 AM

MALVERN, Pa.--(BUSINESS WIRE)--TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced that its Smac mimetic birinapant was presented during an oral session at the 17th Japanese Foundation for Cancer Research – International Symposium on Cancer Chemotherapy (JFCR-ISCC) on December 6 in Tokyo, Japan. Birinapant has entered Phase 2 clinical trials for several solid tumors and a Phase 1/2 study in acute myeloid leukemia (AML) is ongoing. The oral presentation entitled “Birinapant: A Novel Smac mimetic that is Well Tolerated and Active in Hematologic and Solid Malignancies” was part of the JFCR-ISCC’s session on New Drugs under Clinical Trials. The JFCR-ISCC Symposium aims at international cooperation and exchange of information on developments of new molecular-targeted anti-cancer drugs and this year focused on the topic "New antitumor agents under development in the United States, Europe, and Japan.”